Live Breaking News & Updates on தொராசி புற்றுநோய்கள்

Stay updated with breaking news from தொராசி புற்றுநோய்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Study reveals new mutations that make cancer resistant to KRAS-targeted therapies

Study reveals new mutations that make cancer resistant to KRAS-targeted therapies
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.

United States , Jessicaj Lin , Emily Henderson , Termeer Center , Study Co , Drug Administration , Massachusetts General Hospital , Study Co Lead Author , Attending Physician , Thoracic Cancers , Targeted Therapies , ஒன்றுபட்டது மாநிலங்களில் , எமிலி ஹென்டர்சன் , படிப்பு இணை , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை , படிப்பு இணை வழி நடத்து நூலாசிரியர் , கலந்துகொள்வது மருத்துவர் , தொராசி புற்றுநோய்கள் , இலக்கு சிகிச்சைகள் ,

Scientists uncover mutations that make cancer resistant to therapies targeting KRAS

E-Mail
BOSTON - A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year. Unfortunately, cancer cells often develop additional mutations that make them resistant to such targeted drugs, resulting in disease relapse. Now researchers led by a team at Massachusetts General Hospital (MGH) have identified the first resistance mechanisms that may occur to these drugs and identified strategies to overcome them. The findings are published in ....

United States , Mustafa Sakhi , Samuel Klempner , Mohammed Syed , Giulia Siravegna , Aaron Hata , Meagan Ryan , Jochen Lennerz , Chendi Li , Junbing Zhang , Alexa Michel , Bryan Corcoran , Leslie Kiedrowski , Jessicaj Lin , Noritaka Tanaka , Dejan Juric , Justin Gainor , Islam Baiev , Cancer Research , Termeer Center , Mark Foundation For Cancer Research , Drug Administration , Gastrointestinal Cancer Center Program , American Cancer Society , Massachusetts General Hospital , Thoracic Cancers ,

Clinical Challenges: ALK-Positive NSCLC

EML4), producing a unique ALK protein that promotes unchecked, abnormal cell growth.
We see it in about 4-5% of our non-small cell lung cancer patients, so it s a small slice of that pie, Shaw told
Medpage Today. But there are so many non-small lung cell cancer patients out there that even 4-5% is still a large absolute number of patients. And that s not just in the U.S., but worldwide.
The development of targeted therapies for
ALK-positive NSCLC over the past dozen years has had a significant impact on the natural history of the disease. According to Shaw, in the absence of the ALK targeted therapies, ....

United States , Alice Shaw , Jose Pacheco , Novartis Institutes For Biomedical Research , University Of Colorado School Medicine , Translational Clinical Oncology , Novartis Institutes , Biomedical Research , Thoracic Cancers , Massachusetts General Hospital , Colorado School , ஒன்றுபட்டது மாநிலங்களில் , ஆலிஸ் ஷா , ஜோசே ப்யாயேகோ , நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் கொலராடோ பள்ளி மருந்து , மொழிபெயர்ப்பு மருத்துவ புற்றுநோயியல் , நோவர்த்திச் நிறுவனங்கள் , உயிர் மருத்துவ ஆராய்ச்சி , தொராசி புற்றுநோய்கள் , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை , கொலராடோ பள்ளி ,